About this trial
A research study to evaluate the activity of alectinib for the Treatment of pretreated patients with advanced NSCLC that have confirmed RETrearrangement.
Patients with: Histologically or cytologically documented non-small cell lung carcinoma
Advanced disease defined as recurrent stage IV (according to 8th TNM classification) or recurrent or progressive disease following multimodal therapy (radiation therapy, surgical resection, or definitive chemo-radiation therapy for locally advanced disease)
At least one prior platinum-based systemic regimen: Adjuvant or neoadjuvant or definitive platinum-based chemo-radiotherapy treatments are considered as a line of treatment only if completed less than 6 months before enrollment. Maintenance therapy following platinum doublet-based chemotherapy is not considered a separate regimen of therapy.
Where’s this trial being run?St James’s Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.Print this page
For more detailed informationClick Here
|Name:||ETOP 12-17 ALERT|
A Single Arm Phase II Trial Evaluating the Activity of Alectinib for the Treatment of Pretreated RET-rearranged Advanced NSCLC
|Principal Investigator:||Dr. Sinéad Cuffe|
European Thoracic Oncology Platform (ETOP)
Global: June 2018
Ireland: September 2018
|Global Recruitment Target:||44|
|Ireland Recruitment Target:||1-2|